Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00312871|
Recruitment Status : Terminated (Study was stopped due to restrictions in labeling for the subcutaneous route of administration of EPREX.)
First Posted : April 11, 2006
Last Update Posted : May 17, 2011
|Condition or disease||Intervention/treatment||Phase|
|Anemia Renal Failure, Chronic Renal Failure||Drug: Epoetin alfa||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||217 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Early Correction of Anemia on the Progression of Chronic Renal Insufficiency (ECAP)|
|Study Start Date :||February 2001|
|Study Completion Date :||June 2003|
- Rate of progression of chronic renal failure over 36 months as measured by at least 2 glomerular filtration rate assessments.
- Need for renal replacement therapy; quality of life; blood pressure control; hospital admissions; mortality; cardiovascular events; nutritional status.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00312871
|Study Director:||Janssen-Cilag S.A.S. Clinical Trial||Janssen Cilag S.A.S.|